Status:
UNKNOWN
Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection
Lead Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.
Collaborating Sponsors:
Peking University First Hospital
Beijing Hospital
Conditions:
Ventricular Tachycardia
Ventricular Fibrillation
Eligibility:
All Genders
Brief Summary
Retrospective and Prospective single arm, observational study to evaluate efficacy and safety of NIF in the treatment of ventricular tachycardia and ventricular fibrillation. The information registrat...
Detailed Description
Subjects enrolled in the retrospective study may be enrolled in a prospective study if the study drug is re-used, but in the end only the most-registered case of the subject would be collected. The r...
Eligibility Criteria
Inclusion
- Patients with life-threatening ventricular tachycardia or ventricular fibrillation in cases where other drugs are ineffective or inoperable.
- Patients who have received or are about to receive Nifekalant Hydrochloride for treatment according to the instructions.
Exclusion
- \-
Key Trial Info
Start Date :
February 18 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2019
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT03853369
Start Date
February 18 2019
End Date
December 30 2019
Last Update
March 14 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University First Hospital
Beijing, Beijing Municipality, China, 100000